Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | ULK1 | O75385 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26704126 | 0.84 | P2RX7 (0.60) | P2RX7KMT2AAHRMEN1CES1 | |
| SCHEMBL26786803 | 0.80 | P2RX7 (0.51) | P2RX7LOXL2L3MBTL1ULK1 | |
| SCHEMBL16058225 | 0.79 | LOXL2 (0.58) | KMT2ALOXL2MEN1 | |
| SCHEMBL30131477 | 0.79 | LOXL2 (0.58) | KMT2ALOXL2MEN1 | |
| SCHEMBL22290176 | 0.78 | P2RX7 (0.66) | P2RX7KMT2AAHRL3MBTL1MEN1 | |
| SCHEMBL16346448 | 0.78 | P2RX7 (0.61) | P2RX7KMT2AAHRMEN1CES1 | |
| SCHEMBL1219748 | 0.77 | P2RX7 (0.64) | P2RX7KMT2AAHRMEN1CES1 | |
| SCHEMBL109491 | 0.75 | P2RX7 (1.00) | P2RX7KMT2AAHRMEN1CES1 | |
| SCHEMBL14731434 | 0.75 | P2RX7 (0.62) | P2RX7KMT2AAHRL3MBTL1MEN1 | |
| SCHEMBL17298861 | 0.74 | GABRA1 (0.50) | P2RX7LOXL2L3MBTL1FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | P2RX7 3760/4885KMT2A 721/4885LOXL2 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.